These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 5099673)

  • 21. The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist.
    Skeel RT; Sawicki WL; Cashmore AR; Bertino JR
    Cancer Res; 1973 Nov; 33(11):2972-6. PubMed ID: 4748449
    [No Abstract]   [Full Text] [Related]  

  • 22. Synthesis of potential antineoplastic agents. Substituted phenylcyclohexenes.
    Core SK; Lotspeich FJ
    J Med Chem; 1969 Mar; 12(2):334-6. PubMed ID: 4181946
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential anticancer agents. 4. Schiff bases from benzaldehyde nitrogen mustards.
    Shekawat DR; Sabnis SS; Deliwala CV
    J Med Chem; 1972 Nov; 15(11):1196-7. PubMed ID: 4654676
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. VII.
    Venditti JM; Sheldon DR; Goldin A
    Cancer Res; 1964 Jan; 24(1 Pt 1):145-210. PubMed ID: 5878215
    [No Abstract]   [Full Text] [Related]  

  • 25. Potential anticancer agents. 3. Schiff bases from benzaldehyde nitrogen mustards and aminophenylthiazoles.
    Modi JD; Sabnis SS; Deliwala CV
    J Med Chem; 1970 Sep; 13(5):935-41. PubMed ID: 5458385
    [No Abstract]   [Full Text] [Related]  

  • 26. Synthesis and antitumor and antibacterial activity of benzoquinones related to the mitomycins.
    Witty TR; Remers WA
    J Med Chem; 1973 Nov; 16(11):1280-4. PubMed ID: 4201183
    [No Abstract]   [Full Text] [Related]  

  • 27. Synthesis and biological activity of tricyclic antifolate compounds with fixed geometry.
    Rosowsky A; Modest EJ
    Ann N Y Acad Sci; 1971 Nov; 186():258-69. PubMed ID: 5002300
    [No Abstract]   [Full Text] [Related]  

  • 28. Screening data from the Caner Chemotherapy National Service Center Screening Laboratories. XXIX.
    Leiter J; Abbott BJ; Schepartz SA
    Cancer Res; 1965 Dec; 25(11 Pt 2):1779-2061. PubMed ID: 5856668
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacodynamic and pharmacokinetic measurements of antitumor agents.
    Mellett LB
    Clin Pharmacol Ther; 1974 Jul; 16(1):230-42. PubMed ID: 4210526
    [No Abstract]   [Full Text] [Related]  

  • 30. Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine.
    Heby O; Russell DH
    Cancer Res; 1973 Jan; 33(1):159-65. PubMed ID: 4118428
    [No Abstract]   [Full Text] [Related]  

  • 31. Aryl-2-halogenoalkylamines. XXII. Derivatives of phenoxyacetic acid: synthesis and antineoplastic activities.
    Artico M; Ross WC
    Biochem Pharmacol; 1968 Jun; 17(6):873-82. PubMed ID: 5661350
    [No Abstract]   [Full Text] [Related]  

  • 32. Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agents.
    Tagliabue G; Pifferi A; Balconi G; Mascellani E; Geroni C; D'Incalci M; Ubezio P
    Int J Cancer; 1993 May; 54(3):435-42. PubMed ID: 8509218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone) on leukemia L1210.
    Mihich E; Mulhern AI
    Cancer Res; 1968 Feb; 28(2):354-62. PubMed ID: 5641525
    [No Abstract]   [Full Text] [Related]  

  • 34. Some organoboron compounds containing a bis(2-chloroethyl)amino group joined to boron.
    Shealy YF; Struck RF
    J Med Chem; 1969 Sep; 12(5):907-11. PubMed ID: 5812211
    [No Abstract]   [Full Text] [Related]  

  • 35. Aryl-2-halogenoalkylamines. 23. Derivatives of oxanilic acid and salicylic acid: synthesis and antineoplastic activities.
    Artico M; Ross WC
    Biochem Pharmacol; 1968 Jun; 17(6):883-91. PubMed ID: 5661351
    [No Abstract]   [Full Text] [Related]  

  • 36. Substituted-2-desamino-2-methyl-quinazolinones. A series of novel antitumour agents.
    Boyle FT; Matusiak ZS; Hughes LR; Slater AM; Stephens TC; Smith MN; Brown M; Kimbell R; Jackman AL
    Adv Exp Med Biol; 1993; 338():585-8. PubMed ID: 8304185
    [No Abstract]   [Full Text] [Related]  

  • 37. Irreversible enzyme inhibitors. 173. Cure of Walker 256 ascites by reversible and irreversible inhibitors of dihydrofolic reductase derived from 1-(substituted-phenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Vermeulen NM; Ashton WT; Ryan AJ
    J Med Chem; 1970 Nov; 13(6):1130-40. PubMed ID: 5479852
    [No Abstract]   [Full Text] [Related]  

  • 38. Neoplasia, kinetics, nd chemotherapy.
    Hart JS; Livingston RB; Murphy WK; Barlogie B; Gehan EA; Bodey GP
    Semin Oncol; 1976 Sep; 3(3):259-70. PubMed ID: 790580
    [No Abstract]   [Full Text] [Related]  

  • 39. N-Farnesyloxy-norcantharimide and N-farnesyl-norcantharimide inhibit the progression of leukemia and increase survival days in a syngeneic mouse leukemia model.
    Chang MC; Tsai ET; Wu JY; Liao HF; Chen YJ; Kuo CD
    Anticancer Drugs; 2015 Jun; 26(5):508-17. PubMed ID: 25588161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anticancer agents and oncogene function inhibitors of microbial origin].
    Umezawa K; Takeuchi T
    Yakugaku Zasshi; 1988 Dec; 108(12):1129-40. PubMed ID: 3074995
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.